miR-205-5p inhibits human endometriosis progression by targeting ANGPT2 in endometrial stromal cells

article OA: gold CC0 ⤵ 25 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-08

miR-205-5p suppresses endometriosis progression by targeting ANGPT2 and inhibiting the ERK/AKT pathway in endometrial stromal cells, with expression levels correlating to disease severity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-10

This study examined microRNA profiles in ectopic endometrial (endometriosis) tissues versus normal endometrium, using miRNA microarray analysis followed by qRT-PCR validation, and then tested the functional role of the most downregulated miRNA, miR-205-5p. In primary ectopic endometrial stromal cells and a human endometrial-like xenograft model, miR-205-5p overexpression suppressed cell migration, invasion, and promoted apoptosis, while ANGPT2 was identified as a direct miR-205-5p target via luciferase reporter assays; rescuing/silencing ANGPT2 reversed/simulated miR-205-5p effects and implicated ERK/AKT pathway activation. The authors report correlations between miR-205-5p/ANGPT2 expression and endometriosis severity, but the clinical comparison used a small tissue microarray discovery set (n=3 per group). This paper is centrally about endometriosis — specifically how miR-205-5p inhibits endometriosis progression by targeting ANGPT2 and modulating ERK/AKT signaling.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: miRNA expression profiles in ectopic endometrium (EC) serving as pathophysiologic genetic fingerprints contribute to determining endometriosis progression; however, the underlying molecular mechanisms remain unknown. METHODS: miRNA microarray analysis was used to determine the expression profiling of EC fresh tissues. qRT-PCR was performed to screen miR-205-5p expression in EC tissues. The roles of miR-205-5p and its candidate target gene, angiopoietin-2 (ANGPT2), in endometriosis progression were confirmed on the basis of both in vitro and in vivo systems. miR-205-5p and ANGPT2 expression were measured by in situ hybridization and immunochemistry, and their clinical significance was statistically analysed. RESULTS: miR-205-5p was screened as a novel suppressor of endometriosis through primary ectopic endometrial stromal cell migration, invasion, and apoptosis assay in vitro, along with endometrial-like xenograft growth and apoptosis in vivo. In addition, ANGPT2 was identified as a direct target of miR-205-5p through bioinformatic target prediction and luciferase reporter assay. Re-expression and knockdown of ANGPT2 could respectively rescue and simulate the effects induced by miR-205-5p. Importantly, the miR-205-5p-ANGPT2 axis was found to activate the ERK/AKT pathway in endometriosis. Finally, miR-205-5p and ANGPT2 expression were closely correlated with the endometriosis severity. CONCLUSION: The newly identified miR-205-5p-ANGPT2-AKT/ERK axis illustrates the molecular mechanism of endometriosis progression and may represent a novel diagnostic biomarker and therapeutic target for disease treatment.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Angiopoietin-2 Endometriosis Endometrium Mesenchymal Stem Cells MicroRNAs Angiopoietin-2 Angiopoietin-2 Animals Apoptosis Cells, Cultured Endometriosis Endometriosis Endometrium Endometrium Female Humans Mesenchymal Stem Cells Mice Mice, Nude MicroRNAs

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (50)

Cited by (25)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:22:29.487098+00:00
License: CC0 · commercial use OK